Numinus Wellness Inc. Reports Q2 2023 Results

Rhea-AI Summary

Numinus Wellness reported substantial financial growth in Q2 2023, with revenues soaring by 581.1% year-over-year to $5.4 million. Gross profit increased by 820.9% to $2.1 million, alongside a rise in gross margin to 39.3% from 29.1% in Q2 2022. Despite a slight sequential revenue decline of 5.5% due to seasonal impacts, the company's cash position remains robust at $19.7 million. The recent acquisition of Novamind contributed significantly to growth, and the firm is advancing a new licensing model to lower expansion costs. Numinus also plans to enhance its digital platforms for better practitioner training and client support, positioning itself as a leader in psychedelic-assisted therapies.

Positive

• Q2 2023 revenues grew 581.1% year-over-year to $5.4 million
• Gross profit increased 820.9% to $2.1 million
• Gross margin improved to 39.3% from 29.1% in Q2 2022
• Strong cash position with $19.7 million
• New licensing model aimed at reducing expansion capital expenditures

Negative

• Sequential revenue declined by 5.5% primarily due to seasonal impacts
• Gross margin decreased by 260 basis points from Q1 2023
• Operational appointments dropped by 2.1% compared to Q1 2023

• Q2 2023 revenues grew 581.1% year-over-year to $5.4 million
• Q2 2023 gross margin increased to 39.3% from 29.1% in Q2 2022
• Gross profit of $2.1 million, increased 820.9% year-over-year
• Strong cash position of $19.7 million
• New licensing model designed to drive accelerated clinic growth with lower capital expenditures

All financial results are reported in Canadian dollars unless otherwise stated.

VANCOUVER, BC, April 13, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three and six months ended February 28, 2023 ("Q2 2023" and "first six months").

"We are excited about our recently announced training and licensing growth initiatives, which position Numinus as a clear leader in delivering and supporting psychedelic-assisted therapies – and contribute to much needed clinical infrastructure for a sector that is on the verge of significant expansion," said Payton Nyquvest, Founder and CEO. "As we believe that access to these therapies is pending with regulatory reform, the development of clinical protocols, practitioner training, and insurance payor expertise is becoming increasingly important. Given our expansive and growing capabilities, we are one of the best positioned companies to lead the next stage of psychedelic-assisted therapies by providing the necessary infrastructure to deliver these innovative treatments. With new opportunities in sight, we are investing in our digital and licensing platforms to allow us to further scale our business, while reducing the capital investments traditionally needed with clinic expansion."

Commenting on industry dynamics, Mr. Nyquvest added: "Our measured, capital-light approach to growth and diversified service offering continues to elevate Numinus as an industry leader within the changing sector landscape. With clinics that offer an assortment of mental health services, a growing CRO research business that continues to build trusted relationships with drug developers, and an expanded training program to help build the practitioner workforce for the future – Numinus is in a unique position to benefit from reduced competition."

Second Quarter Financial Highlights

• Revenues grew 581.1% year-over-year to $5.4 million in Q2 2023. Sequentially, revenues declined 5.5% from the prior quarter due mostly to seasonal impacts, including fewer operating days as a result of December holidays and February being a short month. (There were 6.25% fewer operating days during Q2 2023 compared to Q1 2023.)
• Gross margin grew to 39.3% during Q2 2023 compared to 29.1% in Q2 2022. The improvement in gross margin is due mostly to the completion of the Novamind acquisition between periods and the offering of higher-margin services. Sequentially, gross margin declined 260 basis points from 41.9% in Q1 2023, due to there being fewer revenue producing days during the quarter.
• Gross profit was $2.1 million in Q2 2023, a significant increase compared to gross profit of $0.2 million in Q2 2022.
• Cash balance of $19.7 million as of February 28, 2023.

First Six Months Financial Highlights

• Revenues grew 600.0% year-over-year to $11.0 million in the first six months of fiscal 2023 compared to the same period last year, due mostly to the acquisition of Novamind.
• Gross margin grew to 40.7% during the first six months of 2023 compared to 17.8% in the same period last year. The improvement in gross margin is due mostly to the completion of the Novamind acquisition between periods and the offering of higher-margin services.
• Gross profit was $4.5 million in the first six months of 2023, a significant increase compared to gross profit of $0.3 million in the same period last year.

Operational Highlights During and Subsequent to Q2 2023

Numinus Wellness Clinic Network

• Wellness clinics generated $4.7 million of revenue during Q2 2023, a 596.9% increase compared to $0.7 million during the same period last year and a 9.9% sequential decline from $5.0 million in Q1 2023, mostly due to there being fewer operating days during the quarter.
• During Q2 2023, Numinus completed more than 19,350 client appointments – including one-on-one and group therapy sessions, neurology-related appointments, paid group programs, Ketamine-assisted psychotherapy (KAT), Transcranial Magnetic Stimulation (TMS) and Ketamine/Spravato medicine appointments, representing a 2.1% decrease in clinic appointments compared to more than 19,774 appointments in Q1 2023, due to there being fewer operating days during the quarter.
• Adjusted for seasonal impact, the average number of appointments per operating day increased by 4.4% (Q2 2023: 322.5 average appointments per day; Q1 2023: 309.0 average appointments per day)
• 8.7% of appointments during Q2 2023 were made by new clients.
• 16.0% of appointments during Q2 2023 were KAT or Ketamine/Spravato medicine related.
• 6.3% of appointments during Q2 2023 were for TMS services.
• Numinus is in the process of transforming its Practitioner model in Canada, with the aim of attracting a greater number of dedicated full-time practitioners. The Company believes this approach will drive greater engagement and clinic utilization rates but may result in fewer practitioners as each can accept more client appointments.
• At the end of Q2 2023, Numinus had 133 practitioners (Q1 2023: 138) providing client treatments through its wellness clinics and virtual services, a 3.6% decrease from the end of the previous quarter.

Numinus Clinical Research

• Revenues from Cedar Clinical Research ("CCR") during Q2 2023 were $0.6 million, a 9.9% decline compared to prior quarter. CCR revenue streams are generated through the management of third-party clinical trials that use CCR's two clinical research sites.
• CCR managed 16 clinical trials during Q2 2023, which included 152 clinical trial patient appointments.
• On February 1, 2023, Numinus announced that it has received approval from Health Canada for its experiential training study that will test the safety and clinical efficacy of whole Psilocybe cubensis tea for therapeutic use, and enable practitioners to further their understanding of psychedelic-assisted therapy through experiential training.
• On February 17, 2023, Numinus announced that CCR expanded into Phoenix, Arizona, with its third clinical research site. The new site is already accepting clinical trial participants for a third-party study that began mid-March, and was recently awarded a second research study.

Corporate Highlights During and Subsequent to Q2 2023

• On February 15, 2023, Numinus announced that all resolutions passed at its Annual General and Special Meeting of Shareholders.
• On March 27, 2023, Numinus launched the Numinus Certification Pathway – a collection of psychedelic-assisted therapy ("PAT") training courses uniquely selected to provide practitioners with complete PAT training, including an experiential component and practicum.
• On April 11, 2023, Numinus announced the launch of its new Numinus Network wellness clinic licensing platform – providing independent practitioners with the opportunity to own and operate a Numinus branded full-service clinic. Numinus Network clinic owners will receive training on all Numinus therapy protocols and administrative and marketing support, among other service offerings.
• On April 11, 2023, Numinus also announced a new partnership with Healing Commercial Real Estate Inc. ("Healing CREI") – a health care focused real estate investment company with deep market knowledge of the psychedelic sector. Through this agreement, Numinus Network licensees will have the option of leasing a turnkey, fully functioning Numinus Wellness clinic location – complete with leasehold improvements and clinic infrastructure, directly from Healing CREI.
• Numinus is in process of investing in its digital platform, to provide effective technology-enabled practitioner training, client booking, and patient support tools, as a foundation for continued clinic and service expansion. The Company believes that its digital platform may become a key driver of growth as it pursues industry partnerships and expands its psychedelic-assisted therapy practitioner training programs.

Q2 2023 Key Performance Metrics

		For the quarter ended February 28:
	2023		2022	% change
Numinus Clinic Network revenues		4,739,609	680,138	596.9 %
Numinus Clinical Research revenues		614,932	105,966	480.3 %
Total Revenue		$5,354,541	$786,104	581.1 %
Cost of revenue		(3,247,983)	(557,345)	482.8 %
Gross Profit (Loss)		$2,106,558	$228,759	820.9 %
Gross profit margin		39.3 %	29.1 %	1020 bps
General and administrative expenses		7,521,707	4,725,878	59.2 %
Share-based compensation		513,034	1,629,890	-68.5 %
Sales and marketing expenses		463,640	429,645	7.9 %
Depreciation & Amortization		425,551	128,820	230.3 %
Research and development expenses		275,839	474,514	-41.9 %
Transaction costs		-	19,830	-100.0 %
Loss before other items		$(7,093,213)	$(7,179,818)	-1.2 %
Other items		(199,731)	(172,280)	n.m.
Revaluation of contingent liability		--	(485,504)	n.m.
Income tax (expense) recovery		(38,542)	--	n.m.
Net Loss		$(7,331,486)	$(7,837,602)	-6.9 %
Other comprehensive income		36,834	--	n.m.
Comprehensive Loss		$(7,294,652)	$(7,837,602)	-6.9 %
Loss per share, basic and diluted		$(0.03)	$(0.04)	-26.6 %
Average number of shares outstanding, basic and diluted		260,213,874	205,209,976	26.8 %

Numinus' condensed consolidated financial statements for the three and six months ended February 28, 2023 and related management's discussion and analysis are available on Numinus' Investor Relations website at www.investors.numinus.com and under the Company's profile on SEDAR at www.sedar.com. These documents were prepared in accordance with IFRS.

Conference Call and Webcast Details
Interested parties are invited to participate in the Company's Q2 2023 results conference call and webcast occurring today, at 5:30 p.m. Eastern time / 2:30 p.m. Pacific time. During the call, Numinus executives will review the Company's performance and recent initiatives, and answer questions from analysts.

To listen to the live webcast, please register at: https://events.q4inc.com/attendee/711589893

The webcast will also be archived on the Events and Presentations page of Numinus' Investor Relations website: https://www.investors.numinus.com/events-and-presentations

To participate in the live conference call, please use the following dial-in information:

• 1 (888) 330-3632 (Toll-free North America)
• 1 (646) 960-0837 (International)
• Please ask to participate in Numinus' Q2 2023 Results Call.
• To avoid any delays in joining the call, please dial in at least five minutes prior to the call start time. If prompted, please provide conference passcode 3547386.

A replay of the conference call can also be accessed after 8:30 p.m. Eastern time / 5:30 p.m. Pacific time on April 13, 2023, at 1-800-770-2030 or 1-647-362-9199 (using passcode 3547386). The replay will be available until April 27, 2023.

About Numinus
Numinus Wellness (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model - including psychedelic production, research and clinic care - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Learn more at www.numinus.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.

Disclaimer
Neither Numinus Wellness Inc., nor any of its subsidiaries is a professional corporation licensed to practice health services. In jurisdictions where health services may only be provided by a corporation if that corporation holds a valid permit to do so, Numinus and its subsidiaries operate in a management services function to affiliated professional corporations, who provide health services to patients. Numinus and its subsidiaries do provide health services directly to patients in those jurisdictions where authorized to do so.

Forward-looking statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are "forward-looking statements". Forward-looking statements can be identified by the use of words such as "expects", "does not expect", "is expected", "believes", "intends", "anticipates", "does not anticipate", "believes" or variations of these words, expressions or statements, that certain actions, events or results "may", "could", "would", "might" or "will be" taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, interest in, uptake of and the ability to commercialize the Numinus Network program, interest in and uptake of the Healing CREI offering from Numinus Network members, availability of suitable locations or licensees for the Numinus Network offering, interest in, uptake of and the ability to commercialize the practitioner training service offering, our ability to recruit dedicated practitioners in Canada, our ability to develop, launch, commercialize and/or maintain the digital tools and service offering, dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate and expand the Company's facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal, state and provincial legalization, if any, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company's limited operating and profitability track record; dependence on management; the Company's need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the impact of the Russia-Ukraine conflict on the global economy; the continued impact of the COVID-19 pandemic; and the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers and other risk factors set forth in our annual information form dated December 12, 2022 and available on SEDAR at www.sedar.com. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company's efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws.

View original content:https://www.prnewswire.com/news-releases/numinus-wellness-inc-reports-q2-2023-results-301797175.html

SOURCE Numinus Wellness Inc.

FAQ

What were Numinus Wellness's Q2 2023 revenues?

Q2 2023 revenues for Numinus Wellness increased by 581.1% year-over-year to $5.4 million.

How much did Numinus Wellness's gross profit increase in Q2 2023?

Gross profit for Q2 2023 soared by 820.9%, reaching $2.1 million.

What is Numinus Wellness's cash position as of February 28, 2023?

As of February 28, 2023, Numinus Wellness held a strong cash position of $19.7 million.

Did Numinus Wellness's revenue decline sequentially in Q2 2023?

Yes, Numinus Wellness experienced a sequential revenue decline of 5.5% in Q2 2023 due to seasonal factors.

What changes has Numinus Wellness made to its licensing model?

Numinus Wellness has implemented a new licensing model aimed at facilitating clinic growth while reducing capital expenditures.